key: cord-0931902-m3um6ptf
authors: Martin-Blondel, Guillaume; Marcelin, Anne-Genevieve; Soulié, Cathia; Kaisaridi, Sofia; Lusivika-Nzinga, Clovis; Dorival, Céline; Nailler, Laura; Boston, Anaïs; Melenotte, Cléa; Gaube, Géraldine; Choquet, Christophe; Liblau, Roland; Carrat, Fabrice; Yordanov, Youri
title: Outcome of very high-risk patients treated by Sotrovimab for mild-to-moderate COVID-19 Omicron, a prospective cohort study (the ANRS 0003S CoCoPrev study)
date: 2022-04-07
journal: J Infect
DOI: 10.1016/j.jinf.2022.04.010
sha: 3a588de358886f878fe1a966504179a0e58cb20b
doc_id: 931902
cord_uid: m3um6ptf

nan

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related coronavirus disease 2019 (COVID-19) manifests with symptoms ranging from fully asymptomatic to severe disease. Many risk factors have been identified in the progression of COVID-19 into a severe stage, including old age, male gender, underlying comorbidities, immunodeficiencies, and pregnancy 1 . The neutralizing antibodies targeting the Spike protein Casirivimab/Imdevimab 2 and Sotrovimab 3 , and the protease inhibitor Nirmatrelvir 4 have been shown to reduce the risk of COVID-19-related hospitalization and death in patients with mild-to-moderate and who are at high risk for progression. However, those studies conducted between Sept. 2020 and Dec. 2021 (during the Alpha and Delta waves) did not assess the effect of those investigational therapeutic agents on the Omicron BA.1 (B.1.1.529) variant of concern (VOC) that emerged in Nov. 2021 before becoming dominant in France, and worldwide 5 . Compared to Delta, Omicron was shown to totally escape the antibody cocktail Casirivimab/Imdevimab, while Sotrovimab, targeting a receptor binding domain epitope outside the ACE2-binding site, retains (although reduced) an in vitro activity 6 . Clinical efficiency of Sotrovimab to prevent COVID-19 related complications in high-risk patients with mild-to-moderate COVID-19 Omicron remains unknown. Our aim was to compare the outcome of Omicron and Delta-infected patients who received respectively Sotrovimab and Casirivimab/Imdevimab.

Our study is based on the ANRS 0003S CoCoPrev study (NCT04885452), an ongoing multicentric prospective cohort study that includes patients considered to be at high-risk for progression to severe COVID-19, having PCR-proven mild-to-moderate COVID-19 in the first five days of symptoms, and who are treated under an emergency use authorization (EUA) in one of the 32 participating centers. Treatment initiation, based on French Health Authorities recommendation, was left at the treating physician discretion. Delta-infected patients included in the cohort were treated by 600/600 mg or 1200/1200 mg of Casirivimab/Imdevimab IV (from Sept 21 th 2021 to Jan 14 th 2022), while Omicron-infected patients received 500 mg of Sotrovimab IV (from Jan 24 th until Mar 3 rd 2022). The primary outcome was the proportion of patients with COVID-19-related hospitalization or death within one month of treatment administration. Secondary outcome was the slope of the Table 1 ). All had mild-to-moderate COVID-19, and risk factors for severe COVID-19, including being > 65 years-old (76/249, 31%) and being immunocompromised (191/249, 77%). Patients who received Sotrovimab were more often fully vaccinated (≥ 3 doses, 77/116, 77%) than patients who received Casirivimab/Imdevimab (56/133, 54%, p=0.002), and had higher median IgG anti-Spike serum level (408 BAU/mL (Q1-Q3: 95-3735) versus 148 BAU/mL (Q1-Q3 41-449), p=0.03). Among patients with available data at the 28 th day visit after treatment administration, respectively 3/129 (2% -95% Clopper-Pearson CI: 1%-7%) and 2/63 (3% -95% Clopper-Pearson CI: 0%-11%) patients who received Casirivimab/Imdevimab or Sotrovimab were hospitalized due to COVID-19, and none died.

All were immunocompromised patients. Median time between administration of Casirivimab/Imdevimab or Sotrovimab and hospitalization was respectively 2 days (Q1-Q3: 1-16) and 4 days (Q1-Q3: 0-7). The slope of Ct values, adjusted on immunosuppressive conditions, was lower in patients who received Sotrovimab (n=75) than in patients who received Casirivimab/Imdevimab (n=66) (p <0.0001, Figure 1 ). No major side effect was reported by the treating physicians.

In this prospective real-life cohort study that included mainly severely immunocompromised patients with mild-to-moderate COVID-19, early administration of Sotrovimab in Omicroninfected patients was associated with a low rate of COVID-19-related hospitalization within one month after treatment administration, and with no death. We would nevertheless argue that our population with a high proportion of severely immunocompromised patients would still exhibit a high likelihood of severe COVID-19 without intervention. Second, the proportion of Omicron-infected patients who received a booster vaccine dose was higher. However, among patients with a known serum IgG anti-Spike status at baseline, 41% were negative, and among those who were positive, the median IgG anti-Spike level might be considered as low.

In conclusion, Sotrovimab was found to effectively protect from progression very high-risk

Omicron-infected patients with mild-to-moderate COVID-19. However, emergence of Omicron BA.2 that contains compared to BA.1 eight unique mutations in the spike protein, and which was shown to escape Sotrovimab 9 , may abrogate this protection, highlighting the urgent need for availability of therapeutic strategies that could adequately treat all sublineages of the Omicron variant, and future emerging variants.

Contributions GM (guarantor) was involved in the study conception, data extraction, data analysis, interpretation of results and drafting the manuscript. AGM was involved in the study conception, data extraction, data analysis, interpretation of results and drafting the manuscript. CS was involved in the study conception, data extraction, data analysis, interpretation of results and drafting the manuscript. SK was involved in data extraction, data analysis, interpretation of results and drafting the manuscript. CLN was involved in data extraction, data analysis, interpretation of results and drafting the manuscript. CD was involved in the study conception, data extraction, data analysis, interpretation of results and revising the manuscript. LN was involved in the study conception, data extraction, data analysis, interpretation of results and revising the manuscript. AB was involved in the study conception, data extraction, data analysis, interpretation of results and revising the manuscript. CM was involved in patients inclusion and revising the manuscript. GG was involved in patients inclusion and revising the manuscript. CC was involved in patients inclusion and revising the manuscript. RL was involved in the study conception, interpretation of results and revising the manuscript. FC was involved in the study conception, data extraction, data analysis, interpretation of results and drafting the manuscript. YY. (guarantor) was involved in the study conception, data extraction, data analysis, interpretation of results and drafting the manuscript.

The ANRS0003S COCOPREV cohort is conducted with the support of ANRS│MIE and funded by French ministries : Ministère desSolidarités et de la Santé and Ministère de l'Enseignement Supérieur, de la Recherche et de l'Innovation» Ethical approval: This study received the ethical approval of the Comité de Protection des Personnes SUD-EST IV).

GM and YY (the manuscript's guarantors) affirm that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned have been explained.

All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work. Omicron-infected patients treated with Sotrovimab. The p-value for the slope difference is < 0.0001.

Chronic diseases, health conditions and risk of COVID-19-related hospitalization and in-hospital mortality during the first wave of the epidemic in France: a cohort study of 66 million people. The Lancet Regional Health

REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19

Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

Nextstrain: real-time tracking of pathogen evolution

Considerable escape of SARS-CoV-2 Omicron to antibody neutralization

The impact of neutralizing monoclonal antibodies on the outcomes of COVID-19 outpatients: A systematic review and metaanalysis of randomized controlled trials

Comparison of Patients Infected With Delta Versus Omicron COVID-19 Variants Presenting to Paris Emergency Departments

Antibody evasion properties of SARS-CoV-2 Omicron sublineages

We thank Pr Yazdan Yazdanpanah and all the ANRS-MIE team for their invaluable support and help.